New Daily Pill for Chronic Weight Management in Adults

Foundayo (orforglipron; pronounced fown-DAY-oh) is a small-molecule GLP-1 receptor agonist taken as a tablet once a day. It is not an injectable GLP-1 (semaglutide, tirzepatide, liraglutide). It is not insulin. It is meant to be used with a reduced-calorie diet and increased physical activity.

The FDA labelled it on 1 April 2026 for chronic weight management in adults with obesity, or adults with overweight who also have at least one weight-related comorbidity. The US label says concomitant use with another GLP-1 receptor agonist is not recommended. The USPI does not carry a standalone type 2 diabetes indication — even though Trial 2 enrolled people with T2D for the weight endpoint, and even though the UK separately authorised a T2D glycaemic-control use.

The UK MHRA authorised Foundayo on 10 August 2026 for weight management and to improve glycaemic control in people with insufficiently controlled type 2 diabetes. That UK T2D line is real. It does not travel onto a US prescription pad. A US clinic uses the USPI. A UK clinic uses the MHRA SmPC.

Canada’s drug agency has an active reimbursement review (SR0955-000) filed Pre NOC. That is under review, not a Notice of Compliance, and not a no.

This is not a cure. It is not labelled for children. It is not a substitute for bariatric surgery counselling when that is the right conversation. Buying a GLP-1 tablet from an unregulated seller is dangerous and, in the UK, promoting prescription-only medicines to the public is illegal.

Where this is taking place

Week 72 pivotal readouts are done. Trial 1 remains active but no longer taking new patients for long-term follow-up. Trial 2 is completed. Neither is a new first-script enrolment slot. Access in the United States is a commercial prescription. Access in the UK is a labelled prescription that is not currently NHS-funded.

Trial 1 — NCT05869903 — Phase 3, adults with obesity (BMI ≥30) or overweight (BMI 27–<30) plus ≥1 weight-related comorbidity; type 2 diabetes excluded. n=3,127. Status active but no longer taking new patients. Sponsor: Eli Lilly and Company. Primary completion 25 Jul 2025. Estimated completion Oct 2027. No expanded access listed. CT.gov countries: United States, Brazil, China, India, Japan, Puerto Rico, Slovakia, South Korea, Spain, Taiwan. No Canadian sites.

Trial 2 — NCT05872620 — Phase 3, adults with BMI ≥27 and type 2 diabetes (HbA1c 7–10%; oral agents allowed except DPP-4 inhibitors / GLP-1 RAs; injectables including insulin excluded). n=1,613. Status completed (completion 8 Aug 2025). Sponsor: Eli Lilly and Company. No expanded access listed. CT.gov countries include United States, Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, Puerto Rico, South Korea. No Canadian sites.

These are historical trial geographies, not a walk-in clinic directory, and not a Canadian DIN.

Commercial supply (labelled): United States (weight management). United Kingdom (weight management and T2D glycaemic control; not currently NHS). Canada: Pre NOC / under review. EMA and other regulators not confirmed on this page: authorisation not retrieved.

Approval matrix

The US line is weight management only. The UK line is weight management and T2D glycaemic control. Your doctor will follow the label of the country where it is prescribed.

Access by country

• United States: Clinician experienced in obesity / weight management (and your usual diabetes clinician if you have T2D as a comorbidity). FDA-labelled 1 Apr 2026 for adults with obesity, or overweight plus ≥1 weight-related comorbidity, with diet and activity. Once daily, with or without food. Swallow whole. Titrate: 0.8 mg → 2.5 mg → 5.5 mg (each step ≥30 days), then may go to 9 / 14.5 / 17.2 mg (≥30 days each); max 17.2 mg. Do not combine with another GLP-1 RA. Strong CYP3A4 inhibitor → max 9 mg; avoid ritonavir-class strong CYP3A4+OATP1B; avoid strong CYP3A4 inducers; simvastatin ≤20 mg. If on oral hormonal contraception: non-oral method or add barrier for 30 days after start and after each escalation. Boxed warning: thyroid C-cell tumors — do not use if personal/family MTC or MEN2. Tell surgeons you are on Foundayo before anesthesia. Lilly US: 1-800-545-5979 / www.foundayo.com. Adverse events: same number or FDA MedWatch 1-800-FDA-1088. Pregnancy registry: 1-800-545-5979. No copay dollars here. Prior authorization still applies. Children not established. US script = weight management label — not a UK T2D licence.

• United Kingdom: MHRA authorised 10 Aug 2026 for weight management and glycaemic control in insufficiently controlled type 2 diabetes. Prescription-only. Not currently available via the NHS; NICE evaluation will follow established processes. Ask the clinic that already manages weight or diabetes; do not assume NHS routine funding; do not buy from unregulated sellers. Same once-daily tablet titration language as the US (0.8 through 17.2). Yellow Card for suspected side effects. A US bottle is not a UK NHS entitlement.

• Canada (does not change the access level shown above): No retrieved NOC. CDA-AMC SR0955-000 is Active, filed Pre NOC, Eli Lilly Canada Inc., brand name not yet confirmed. That is a reimbursement review clock, not a marketed DIN. Under review is not a no. Provincial / territorial / NIHB / RAMQ listings are unknown / not confirmed on this page (N/A until NOC). ATTAIN / Trial 1 and Trial 2 had no Canadian sites on CT.gov — those trials are not a Canadian enrolment route. SAP for a non-marketed drug is unknown. Do not mail-order a US bottle. This Canada note does not change the access level shown above.

• European Union: Authorisation not retrieved as an EC MA. MHRA said the UK was first in Europe. Wait for an EMA/EC decision before treating an EU pack as real. Do not DIY-import.

• Australia / Japan / China / Switzerland: Authorisation not retrieved. Trial geography ≠ licence. Specialist + local special-access / trial only if those programs apply.

If your regulator has not authorised it: do not import on your own. Do not buy from unregulated online sellers.

Who is eligible (from the labels — they are not the same)

United States (USPI):

• Age 18+ (adults).
• Obesity, or overweight with ≥1 weight-related comorbid condition.
• Use with reduced-calorie diet and increased physical activity.
• Do not combine with another GLP-1 receptor agonist.
• Dose: 0.8 → 2.5 → 5.5 → (optional) 9 / 14.5 / 17.2 mg once daily; ≥30 days per step; max 17.2 mg.
• Pediatrics: not established.
• Contraindications: personal/family MTC or MEN2; serious hypersensitivity to orforglipron or excipients.
• Not a standalone US type 2 diabetes indication on this USPI (people with T2D appear in Trial 2 for the weight endpoint and in safety language — that is not a T2D-as-primary US label).

United Kingdom (MHRA GOV.UK):

• Weight loss and weight maintenance in adults with BMI ≥30, or BMI 27–30 with ≥1 weight-related comorbidity — and
• Improve glycaemic control in insufficiently controlled type 2 diabetes.
• Same tablet; prescription-only; not currently NHS.

Canada (CDA requested criteria — not a NOC):

• Applicant asked for weight-management wording similar to the US BMI lines (obesity ≥30 or overweight 27–<30 + comorbidity, listing T2D among example comorbidities). That is not a Health Canada licence until there is a NOC.

What the pivotal studies showed (use the USPI)

These numbers are from USPI Table 6 (Week 72 mean % change in body weight), not from a press release.

Trial 1 (NCT05869903) — without type 2 diabetes:

• Placebo −2.1%
• Foundayo 5.5 mg −7.4%; 9 mg −8.3%; 17.2 mg −11.1%
• ≥5% weight loss at 17.2 mg: 71.5% vs placebo 26.8%
• ≥10% at 17.2 mg: 54.5% vs 13%
• ≥15% at 17.2 mg: 35.9% vs 6%

Trial 2 (NCT05872620) — with type 2 diabetes:

• Placebo −2.5%
• Foundayo 5.5 mg −5.1%; 9 mg −7%; 17.2 mg −9.6%
• ≥5% weight loss at 17.2 mg: 67% vs placebo 26.8%
• ≥10% at 17.2 mg: 45.6% vs 9.2%
• HbA1c also fell more on Foundayo than placebo in Trial 2 (USPI Table 7) — that supports the weight trial design in people with T2D; it does not create a US standalone T2D indication.

All patients received lifestyle counselling (reduced-calorie diet; ≥150 minutes activity/week recommended). This is weight reduction at 72 weeks with diet and activity. It is not a proven cardiovascular-outcomes label on the documents checked here. A US clinic should use the USPI tables.

How it is taken (US label)

• One tablet once daily, any time, with or without food.
• Swallow whole. Do not break, crush, or chew.
• Do not take more than one tablet per day.
• Titration (to reduce GI side effects):
• Start 0.8 mg once daily.
• After ≥30 days → 2.5 mg.
• After ≥30 days → 5.5 mg.
• Then, if needed and tolerated, after ≥30 days each: 9 mg, then 14.5 mg, then 17.2 mg.
• Maximum 17.2 mg once daily.
• Strong CYP3A4 inhibitor: maximum 9 mg. Avoid strong CYP3A4+OATP1B (e.g. ritonavir). Avoid strong CYP3A4 inducers.
• Missed dose: take as soon as possible; do not double up. If 7 or more consecutive doses missed, restart escalation at a lower dose with the clinician (GI risk).
• Store 20–25 °C (excursions 15–30 °C) in the bottle with desiccant / child-resistant cap.

Safety (USPI)

Boxed warning — thyroid C-cell tumors. Class language for GLP-1 receptor agonists. Orforglipron is not active in rats/mice and did not produce rodent tumors; human relevance of class rodent findings is unknown. Do not use with personal or family history of medullary thyroid carcinoma or with MEN2. Report a neck mass, trouble swallowing, shortness of breath, or persistent hoarseness.

Contraindications: MTC personal/family or MEN2; serious hypersensitivity to orforglipron or any excipient.

Acute pancreatitis. Stop and call for severe persistent abdominal pain (with or without vomiting), sometimes radiating to the back.

Severe gastrointestinal reactions. Common; sometimes severe (~3% vs 1% placebo). Not recommended in severe gastroparesis. Nausea/vomiting/diarrhea peak during escalation and often ease.

Acute kidney injury from volume depletion. Drink fluids if GI losses are ongoing; call for persistent nausea/vomiting/diarrhea.

Hypoglycemia. Risk rises with insulin or sulfonylurea — dose reductions of those agents may be needed. Educate on hypo symptoms even without diabetes (rare glucose <54 mg/dL reported in Trial 1).

Hypersensitivity. Anaphylaxis / angioedema possible with the class — stop and seek care.

Diabetic retinopathy (if T2D). Monitor if you have a retinopathy history; rapid glucose improvement can temporarily worsen retinopathy.

Gallbladder disease. Cholelithiasis / cholecystitis reported; call for upper-abdominal pain, fever, jaundice, clay-colored stools.

Pulmonary aspiration under anesthesia / deep sedation. Delayed gastric emptying. Tell the surgical team before elective procedures.

Most common adverse reactions (≥5%, Trials 1+2 pool, vs placebo): nausea (up to 35% at 17.2 mg vs 10%), constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, GERD, flatulence, hair loss (more in women; associated with weight loss). Permanent discontinuation for AEs ~8% vs 3% placebo; most often GI.

Pregnancy. Discontinue when pregnancy is recognized; weight loss offers no benefit in pregnancy and may harm the fetus. Registry: 1-800-545-5979. Lactation: not recommended. Oral contraceptives: non-oral or add barrier 30 days after initiation and after each dose escalation.

Hepatic: not recommended in severe (Child-Pugh C) impairment. Renal: no dose change for renal impairment; monitor if volume-depleted.

Research team (Who)

Names below are as they appear on primary sources.

• Eli Lilly and Company / Lilly USA, LLC, Indianapolis, IN — FDA applicant / DailyMed packager / USPI “Marketed by.” Medical information / pregnancy registry: 1-800-545-5979 / www.foundayo.com.
• Eli Lilly and Company — NCT05869903 and NCT05872620 lead sponsor.
• Eli Lilly Canada Inc. — CDA-AMC SR0955-000 manufacturer (brand name not yet confirmed).
• Eli Lilly — MHRA authorisation holder named on GOV.UK (10 Aug 2026).
• FDA press quotes Commissioner Martin Makary, M.D., M.P.H. and Acting CDER Director Tracy Beth Høeg, M.D., Ph.D. — regulator voices, not treating clinics.
• MHRA quotes Julian Beach, Executive Director of Healthcare Quality and Access — regulator, not a clinic.

No Canadian site PI exists on these two CT.gov records (no Canadian sites).

How to talk to a doctor

Bring the NCT numbers and the regulator that applies:

1. “I have obesity / overweight with a weight-related condition. The FDA labelled orforglipron (Foundayo) on 1 April 2026 as a once-daily tablet, with or without food, titrated from 0.8 mg toward 17.2 mg. Is that a fit with diet/activity — and with any GLP-1 I am already on?”
2. “The US label is weight management, not a standalone T2D indication. I do / do not have type 2 diabetes — how does that change monitoring (glucose, eyes, other diabetes drugs)?”
3. Drug interactions: “I take simvastatin / a CYP3A4 inhibitor or inducer / ritonavir / insulin or a sulfonylurea. The USPI caps simvastatin at 20 mg and has CYP3A4 rules.”
4. Contraception: “If I use an oral contraceptive, the label wants a non-oral method or added barrier for 30 days after start and after each dose increase.”
5. Boxed warning: “I do / do not have a personal or family history of medullary thyroid cancer or MEN2.”
6. Surgery: “I need elective anesthesia — the label says tell the team because of delayed gastric emptying.”
7. If UK: “MHRA authorised weight management and T2D glycaemic control on 10 Aug 2026. Is this an NHS path yet, or private / waiting on NICE? I will not buy from an unregulated seller.”
8. If Canada: “CDA SR0955 is Pre NOC / under review. Is SAP appropriate, or do we wait for a NOC? There were no Canadian ATTAIN sites on CT.gov for these two trials.”
9. If already on an injectable GLP-1: “The USPI says do not combine with another GLP-1 receptor agonist.”

Canada close-up: Pre NOC / under review / SAP unknown

CDA-AMC SR0955-000 is Active with NOC Status at Filing: Pre NOC. That is not a Notice of Compliance and not a refusal. DIN/SBD unknown / not confirmed on this page. Provincial listings are unknown / not confirmed on this page (N/A until there is a NOC). Trial 1 and Trial 2 had no Canadian sites. SAP unknown. US: labelled weight-management Rx. UK: labelled including T2D, not currently NHS. Do not mail-order.

Bottom line

Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist tablet labelled in the United States on 1 April 2026 for chronic weight management in adults with obesity, or overweight plus a weight-related comorbidity — with diet and activity, titrated from 0.8 mg toward 17.2 mg, with a boxed warning and clear CYP3A4 / simvastatin / oral-contraceptive locks. United Kingdom (10 Aug 2026): weight management and T2D glycaemic control — not currently NHS. Canada: CDA Pre NOC under review, not refused. US weight-only and UK weight+T2D stay separate. Authorized is not funded. Canada is covered separately above.

Primary sources

1. DailyMed FOUNDAYO (orforglipron) USPI / Medication Guide, setid 8ac446c5-feba-474f-a103-23facb9b5c62, NDA 220934, revised 7/2026, marketing start 1 Apr 2026 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
2. FDA press announcement, 1 Apr 2026 — Foundayo (orforglipron) CNPV NME approval — https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
3. MHRA GOV.UK, 10 Aug 2026 — UK authorises orforglipron for weight management and type 2 diabetes — https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes
4. CDA-AMC SR0955-000 orforglipron (Pre NOC, Active) — https://www.cda-amc.ca/orforglipron
5. ClinicalTrials.gov NCT05869903 — https://clinicaltrials.gov/study/NCT05869903
6. ClinicalTrials.gov NCT05872620 — https://clinicaltrials.gov/study/NCT05872620